Older adults are more vulnerable to influenza virus infection and at higher risk for severe complications and influenza-related death compared to younger adults. Unfortunately, influenza vaccine responses tend to be impaired in older adults due to aging of the immune system (immunosenescence). Latent infection with cytomegalovirus (CMV) is assumed to enhance age-associated deleterious changes of the immune system. Although lower responses to influenza vaccination were reported in CMV-seropositive compared to CMV-seronegative adults and elderly, beneficial effects of CMV infection were observed as well. The lack of consensus in literature on the effect of latent CMV infection on influenza vaccination may be due to the presence of pre-existing immunity to influenza in these studies influencing the subsequent influenza vaccine response. We had the unique opportunity to evaluate the effect of age and latent CMV infection on the antibody response to the novel influenza H1N1pdm vaccine strain during the pandemic of 2009, thereby reducing the effect of pre-existing immunity on the vaccine-induced antibody response. This analysis was performed in a large study population (n = 263) in adults (18-52 years old). As a control, memory responses to the seasonal vaccination, including the same H1N1pdm and an H3N2 strain, were investigated in the subsequent season 2010-2011. With higher age, we found decreased antibody responses to the pandemic vaccination even within this age range, indicating signs of immunosenescence to this novel antigen in the study population. Using a generalized estimation equation regression model, adjusted for age, sex, and previous influenza vaccinations, we observed that CMV infection in contrast did not influence the influenza virus-specific antibody titer after H1N1pdm vaccination. Yet, we found higher residual protection rates (antibody level ≥40 hemagglutinin units (HAU)) in CMV-seropositive individuals than in CMV-seronegative individuals 6 months and 1 year after pandemic vaccination. In the subsequent season, no effect of age or CMV infection on seasonal influenza vaccine response was observed. In conclusion, we observed no evidence for CMV-induced impairment of antibody responses to a novel influenza strain vaccine in adults. If anything, our data suggest that there might be a beneficial effect of latent CMV infection on the protection rate after novel influenza vaccination.
Older adults are more vulnerable to influenza virus infection and at higher risk for severe complications and influenza-related death compared to younger adults. Unfortunately, influenza vaccine responses tend to be impaired in older adults due to aging of the immune system (immunosenescence). Latent infection with cytomegalovirus (CMV) is assumed to enhance age-associated deleterious changes of the immune system. Although lower responses to influenza vaccination were reported in CMV-seropositive compared to CMV-seronegative adults and elderly, beneficial effects of CMV infection were observed as well. The lack of consensus in literature on the effect of latent CMV infection on influenza vaccination may be due to the presence of pre-existing immunity to influenza in these studies influencing the subsequent influenza vaccine response. We had the unique opportunity to evaluate the effect of age and latent CMV infection on the antibody response to the novel influenza H1N1pdm vaccine strain during the pandemic of 2009, thereby reducing the effect of pre-existing immunity on the vaccine-induced antibody response. This analysis was performed in a large study population (n = 263) in adults (18-52 years old). As a control, memory responses to the seasonal vaccination, including the same H1N1pdm and an H3N2 strain, were investigated in the subsequent season 2010-2011. With higher age, we found decreased antibody responses to the pandemic vaccination even within this age range, indicating signs of immunosenescence to this novel antigen in the study population. Using a generalized estimation equation regression model, adjusted for age, sex, and previous influenza vaccinations, we observed that CMV infection in contrast did not influence the influenza virus-specific antibody titer after H1N1pdm vaccination. Yet, we found higher residual protection rates (antibody level ≥40 hemagglutinin units (HAU)) in CMV-seropositive individuals than in CMV-seronegative individuals 6 months and 1 year after pandemic vaccination. In the subsequent season, no effect of age or CMV infection on seasonal influenza vaccine inTrODUcTiOn Aging of the population poses an important public health problem. With age, the function of the human immune system declines, a phenomenon also referred to as immunosenescence (1) . Profound changes of the immune system include the gradual loss of naïve cells, increase of memory cell numbers, and decreased diversity of the T cell and B cell repertoire (1) (2) (3) . These changes contribute to reduced protection against infectious diseases and reduced vaccine responses in older adults. Indeed, the incidence of influenza virus infections is increased and accompanied with more complications and higher mortality in older adults (4, 5) . Most developed countries recommend yearly influenza vaccina tion in individuals above 60 or 65 years of age (6) , in order to prevent influenza virus infection by the induction of protective antibodies (4, 7). However, the antibody response to influenza vaccination in older adults is impaired, causing a suboptimal protection in this vulnerable group (7) (8) (9) . Accumulating evidence indicates that latent cytomegalo virus (CMV) infection is associated with agerelated changes of the immune system, and might enhance immunosenescence (2, 10, 11) . CMV is a common βherpesvirus with a prevalence of 45-100% worldwide, which increases with advancing age (12) . CMV infection causes morbidity and mortality in severely immunocompromised patients, while the virus rarely causes clinical symptoms in healthy individuals. Despite the ability of the immune system to control primary infection, the virus establishes a latent infection, with episodes of viral reactivation during lifetime (13) . The frequent reactivation of CMV causes continuous antigenic stress for the immune system (3). Anti CMV IgG levels increase with age (14) (15) (16) and are thought to increase after viral reactivation episodes, thereby reflecting the amount of experienced CMV antigenic stress during lifetime (12, 14, 17) . The profound effect of CMV infection on the immune system is especially shown by the progressive large expansion of oligoclonal CMVspecific CD8 T cells and, to a lesser extent, CD4 T cells. Furthermore, CMVseropositivity is strongly associated with an inverted CD4/8 ratio (18), bias of the TCR repertoire (19) , and an increase of highly differentiated T cells (20) .
It has been suggested that CMVenhanced immunosenescence could impair the immune response to influenza vaccination (21, 22) . Indeed, in several studies, CMVseropositivity or a high antiCMV IgG titer was associated with lower antibody responses to influenza vaccination in both adults (23) (24) (25) and older adults (25) (26) (27) (28) . However, others did not find an effect of CMV infec tion (29, 30) , or reported even an enhanced antibody response to influenza vaccination in both young (31, 32) and older CMVseropositive individuals (33) .
The overall impact of latent CMV infection on the antibody induction by influenza vaccines remains controversial and depends, among other factors, on preexisting immunity to influenza virus (34) . Most studies investigated the antibody response to seasonal influenza vaccination; a yearly recom mended trivalent influenza vaccine that often contains overlap ping influenza vaccine strains in consecutive years. Natural exposure to influenza virus and previous vaccination causes preexisting immunity, which influences the consecutive vaccine response. Higher prevaccination antibody titers (pretiters) indeed were shown to result in lower postvaccination antibody titers to subsequent vaccination (7, 35) . Furthermore, one could expect a larger effect of immunosenescence on de novo immune responses (36, 37) . A seasonal influenza vaccination is, therefore, a suboptimal study setting to investigate the effect of latent CMV infection on influenza vaccine antibody response.
We hypothesize that the effect of latent CMV infection on the antibody response to influenza vaccination can best be studied when a novel influenza virus strain is introduced into a naïve population. In this study, we had the unique opportunity to investigate the effect of latent CMV infection on the antibody response during the pandemic season of 2009 to the novel H1N1pdm vaccine strain in a large study population and at multiple time points after vaccination. This allowed a sophisti cated study design to test the effect of latent CMV infection on a de novo influenza vaccine response by minimizing preexisting immunity due to previous exposure by vaccination or natural infection. As a control, the influence of latent CMV infection on the memory antibody response to the vaccination in the subsequent year was also investigated, which included both the same H1N1pdm vaccine strain and an H3N2 vaccine strain.
MaTerials anD MeThODs study Population and Design
The current study is embedded in a trial that evaluated the immune responses to pandemic and seasonal influenza vaccina tion that was conducted in 2009-2011 (the Pandemic influenza vaccination trial, Netherlands Trial Register NTR2070). This study was carried out in accordance with the recommenda tions of Good Clinical Practice with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Central Committee on Research Involving Human Subjects of the Netherlands. Healthy individuals, between 18 and 52 years of age, were recruited among health care workers in the Utrecht area in the Netherlands. Individuals over 52 years of age were not included because of potential pre existing immunity due to exposure to the influenza A/H1N1 strain that circulated until 1957 (38) . Serum samples and ques tionnaires were used from the vaccine group of the Pandemic influenza vaccination cohort.
Vaccines
In the pandemic season, individuals received two doses of the monovalent MF59adjuvanted influenza vaccine containing influenza A/California/7/2009(H1N1pdm09) with a 3week interval (Focetria, Novartis, Italy). Blood samples were col lected before vaccination (T1), 3 weeks after vaccination at which also the second pandemic vaccine dose was given (T2) 
assessment of serum anti-cMV antibody Titers
AntiCMV IgG antibody concentrations were measured using a commercial ELISA (IBL international GMBH, Hamburg, Germany) according to manufacturer's instructions. Participants with a CMV antibody level of ≥12 U/ml or higher were con sidered CMVseropositive, a level of ≤8 U/ml were considered CMVseronegative, and a level between 8 and 12 U/ml was considered equivocal and these participants were excluded for further analysis. CMVseropositive individuals were divided into low antiCMV levels (≤30 U/ml), medium antiCMV levels (>30 U/ml, ≤90 U/ml), or high antiCMV levels (>90 U/ml) according to the standards in the CMV ELISA kit.
hemagglutination-inhibition (hi) assay
Hemagglutinationinhibition 
statistical analysis
Antibody responses to H1N1pdm influenza vaccination in the pandemic season were expressed in two different ways: (1) influ enza antibody titer and (2) protection rate (antibody titer ≥40 HAU). For all statistical analyses, influenza antibody titers were log (base 2) transformed, and presented as geometric mean titer (GMT) with 95% confidence interval (CI) in the figures. First, a twotailed Student's ttest (for two groups) or one way ANOVA (for three or more groups) was used to explore group differences in influenza antibody titers (e.g., between low, medium, and high CMV IgG groups). For the twotailed Ttest, equality of variances was tested with Levene's test for equality. Group differences in categorical variables were compared with the Fisher exact test.
Second, we investigated the effect of latent CMV infection in a multivariate context; the effect of CMV infection on influenza antibody titers was adjusted for potential confounders using a generalized estimation equation (GEE) regression model (Table S1 in Supplementary Material) (40) . This model takes repeated measurements for the same individuals into account. For the continues variable outcome (influenza antibody titer) the normal distribution and for the categorical variable (influ enza protection rate) the binomial distribution of the model Table S1 in Supplementary Material).
The model yielded a beta regression coefficient for each variable, which reflects how a category (e.g., highest age group) compares to the reference category (e.g., lowest age group). Regression coefficients of the GEE models are given in Tables S2-S7 
negative effect of age on influenza Titers after De Novo Pandemic influenza Vaccination
We investigated if there was an effect of age on the induction of antibodies to the pandemic influenza vaccination in our study population. After pandemic vaccination, H1N1pdm influenza virusspecific antibody titers were negatively correlated with age at all time points postvaccination except T5 (see Table S8 in Supplementary Material). Representative data are depicted for T2 in Figure 2A (T2, p = 0.0013, R = −0.198). Individuals are divided into three age groups for further analysis by approximately 10year intervals. Significant differences were also observed between age groups in the H1N1pdm titers (e.g., T2, p = 0.016), with lower responses in the oldest age group compared to the youngest two age groups (e.g., T2, 19-30 versus 40-52 year p = 0.007) ( Figure 2B ) (see Table S8 in Supplementary Material). Similar results were observed for the different age groups when analyzing the data by protection level, defined by reaching a titer of ≥40 HAU (data not shown). These data indicate that there are already signs of immunosenescencedriven impaired vaccine responses to a novel antigen challenge in middleaged individuals.
no effect of cMV-seropositivity on antibody Titers after Pandemic influenza Vaccination
Next, the effect of latent CMV infection on the influenza virus specific antibody response to the vaccine with the newly intro duced H1N1pdm influenza vaccine strain was investigated. CMVseropositive individuals were compared to CMV seronegative individuals for influenza titers before and after vaccination. No differences between CMVseropositive and CMVseronegative individuals in influenza titer at any time point in both seasons were found ( Figure S1A in Supplementary Material). Some individuals did already show a detectable pan demic titer before vaccination, although on average the pretiter was very low (GMT 9.4 HAU). To correct for this and other potential confounders, influenza titers of CMVseropositive and CMVseronegative individuals were analyzed adjusted for pretiter, sex, age, and previous influenza vaccinations with a GEE model (Table S2 in Supplementary Material). No significant protection rate was observed. However, CMVseropositivity was associated with enhanced 6 months and 1 year protection rates after pandemic vaccination. The percentage influenza protected individuals is significantly higher for CMVseropositive indi viduals than for CMVseronegative individuals, both 26 weeks (p = 0.047) and 52 weeks (p = 0.044) after pandemic vaccination ( Figure 3B ) (unadjusted data in Figure S1B in Supplementary Material). Together, this suggests that latent CMV infection did not impair the protection rate after influenza vaccination, but if anything, might be beneficial for persistence of protection after the de novo influenza vaccination.
high anti-cMV igg levels as surrogate Marker of cMV reactivation are not associated with impaired Pandemic influenza Vaccine response in cMV-seropositive individuals
To study in the CMVseropositive individuals whether the frequency of CMV reactivation has a negative effect on the influenza antibody responses, antiCMV IgG levels were used as a surrogate marker of CMV reactivation (25, 42) and associated with the influenza antibody response to vaccination. To this end, CMVseropositive individuals with low antiCMV IgG levels (≤30 U/ml), medium antiCMV IgG levels (>30 U/ml, ≤90 U/ml) or high antiCMV IgG levels (>90 U/ml) were compared for their influenza antibody titer and protection rate both unad justed (Figures S1C,D in Supplementary Material) and with the GEE model (Table S3 in Supplementary Material). No differences were observed between antiCMV IgG groups in the H1N1pdm influenza titers or protection rate after the pandemic vaccina tion (Figures 3C,D) . This indicates that despite a negative effect of age on the antibody response to the pandemic vaccination (Figure 2) , no signs of impairment by CMV reactivation were observed. Also this shows that the positive effect of CMV status on longterm protection after pandemic influenza vaccination ( Figure 3B ) could not be explained by differences in antiCMV IgG groups within CMVseropositive individuals.
no effect of age or cMV-serostatus on seasonal influenza Vaccination with h1n1pdm and h3n2
The same analyses for the effect of age and latent CMV infection on influenza vaccination were performed for the 128 individuals that continued with the study and were vaccinated in season 2010-2011 with the seasonal influenza vaccination containing the same H1N1pdm strain and an H3N2 strain. A trend of a negative effect of age on the H1N1pdm memory response was observed, but no significant differences in antibody titers for H1N1pdm or H3N2 were found between age groups at any time point after vaccination in season 2010-2011 (e.g., T2, respectively, p = 0.101 and p = 0.434) ( Figure 4A ). Both the influenza antibody titer and the protection rate did not differ between CMVseropositive and CMVseronegative individuals (Figures 4B-D ; Tables S4 and S6 in Supplementary Material) . Surprisingly, influenza antibody titers and protection rate after the differences were found between CMVseropositive and CMV seronegative individuals in antibody titers at each individual time point (Figure 3A ). So although age shows a negative effect on the novel pandemic H1N1pdm antibody response indicative of immunosenescence to de novo response (Figure 2 ), no effect of CMVserostatus on the influenza virus titer is observed after pandemic vaccination in adults ( Figure 3A) .
higher residual Protection rates after Pandemic influenza Vaccination in cMV-seropositive individuals than in cMV-seronegative individuals
Subsequently, we investigated whether there was an effect of CMVserostatus on the protection rate, as defined by antibody titer ≥40 HAU, against influenza virus after influenza vaccination (41) . Shortly after vaccination, no effect of CMVserostatus on the Tables S5  and S7 in Supplementary Material). In summary, although no clear effect of age or CMVserostatus, high antiCMV IgG levels seem to be associated with high influenza antibody titers and protection rate in CMVseropositive individuals.
DiscUssiOn
In this study, we investigated the effect of age and latent CMV infection on the antibody response to a novel influenza vaccine strain in healthy adults. We found evidence of immunosenescence in these adults from the age of 40. However, latent CMV infec tion did not impair the antibody responses to a de novo influenza vaccine response. Interestingly, indications for the contrary were observed: CMVseropositive individuals even showed a higher longterm influenza protection rate after pandemic influenza vaccination. These results suggest that latent CMV infection does not always further weaken agerelated impaired immunity, but if anything, might be beneficial.
Our study showed no negative association between latent CMV infection and the antibody response to influenza vaccina tion. Other studies did report negative effects in adults (23, 25, 32) and older adults (25, 26, 28, 43) . However, most of these studies investigated the effect of latent CMV infection on the influenza vaccine response in the presence of preexisting immunity. In one study, all subjects were even seroprotected (influenza antibody titer >40 HAU) before influenza vaccination (26) . It is known that individuals with high pretiters show a lower increase in influenza antibody response after influenza vaccination (7, 19, 35, 44) . Therefore, high pretiters are associated with lower sero conversion (antibody titer ≥40 HAU and ≥4fold increase) and higher protection rate (>40 HAU). Furthermore, in all but two studies (25, 43) , vaccine history was not taken into account, while previous vaccination is associated with lower seroconversion independently of pretiters (7) . Not accounting for preexisting immunity in influenza vaccine responses, therefore, may obscure findings and lead to different findings on the effect of latent CMV infection. Here, we controlled for preexisting immunity by investigating the effect of latent CMV infection on pandemic vaccination for which preexisting immunity was low, and by performing analysis adjusted for pretiters and vaccine history. By doing so, we found that influenza vaccine responses are not Results for the effect of latent CMV infection are adjusted for sex, age group, and previous influenza vaccinations by a generalized estimation equation (GEE) regression model. Significant differences are tested by pairwise comparison between CMV-seropositive and CMV-seronegative individuals or anti-CMV IgG group high and low per separate time point. Significant differences between age groups were tested with ANOVA and differences between two age groups are tested with Student's t-test for (log transformed) antibody titers. *p < 0.05. A beneficial effect of latent CMV infection on the immune system has been indicated (10) and is suggested to reflect higher activation status of innate cells after primary CMV infection or reactivation. Accordingly, an increased antibody titer short term after influenza vaccination in young CMVseropositive compared to young CMVseronegative individuals was observed (31) (32) (33) and suggested to depend on boosting by lowgrade inflammation and high levels of circulating IFNγ in CMVseropositive young individuals (31, 33) . A beneficial effect of latent CMV infection on the longterm persistence of protection after vaccination in adults has to our knowledge not been reported. Waning of protection is thought to be most significant in individuals above 65 years of age (45) and accelerated by latent CMV infection (46) . Our results might suggest a positive effect of CMV infection in adults on the protection rate. Thereby our data fit in a scenario in which latent CMV infection has a beneficial effect in adults and may become detrimental with aging.
Two studies that reported a shortterm negative effect of latent CMV infection in adults did take the factor preexisting immunity into account by either correcting for antibody titers prevaccination (24) or by investigating the effect of latent CMV infection on the novel pandemic vaccine (23) . However, these studies differ from our study in terms of vaccine type and analysis of the antibody response. Turner et al. studied the fold increase of influenza antibody titers to seasonal vaccination, corrected for pretiters before vaccination (24) . They reported a negative effect on the influenza antibody fold increase in one strain of the tri valent vaccine in CMVseropositive adults with high antiCMV IgG levels compared to CMVseronegative adults. Wald et al. (23) also reported a negative effect of CMVseropositivity in adults, by investigating the same pandemic H1N1pdm vaccine response in 2009 as we did. However, they did not adjust for confounders in the analysis (23) . These differences in findings of the effect of latent CMV infection on the influenza vaccine response without preexisting immunity are unexplained. We speculate that the vaccine dose and adjuvant use may be a reason for these differ ences. In Turner et al., half the recommended dose was used (24) . Likewise, an unadjuvanted monovalent vaccine (47) was used in Wald et al., while in our study the vaccine was adjuvanted. The use of MF59 adjuvant is expected to activate the CD4+ T cells and further enhance antibody production, thereby eliciting a stronger immune response compared to an unadjuvanted vaccine. Taken together, it may be possible that only with less potent influenza vaccines, a shortterm negative effect of latent CMV infection is present.
The correlation of lower antibody response to the novel pandemic influenza vaccination with age points to an immu nosenescencedriven weakened immune response. Typically, lower antibody responses to influenza vaccination are associated with high age (>60 years old). Interestingly, we observed already an effect of age in this group of nonelderly (18-52 years of age), although small. This effect of age was due to a lower influenza antibody response from the age of 40 years onward. It is suggested that differences between age groups to influenza vaccination responses might also explained by HA imprinting (48) . HA imprinting implicates that the immune response is skewed to the group of HA antigens of the influenza strain that is first encountered during childhood. However, this was not the case and HA imprinting could be excluded as an explanation for the age differences.
Similar analyzes were performed for the effect of age and latent CMV on the seasonal influenza vaccine response in season 2010-2011. Seasonal vaccination in 2010-2011 con tained the same H1N1pdm strain of the pandemic season and the antigendrifted H3N2 strain that overlaps in serological response to great extent with previous H3N2 strains (49) . Thus, both seasonal strains elicit an immunological memory response. Immunosenescence mainly affects the de novo immune responses (36, 37) . In line with this, effects of age on an influenza vac cine response diminish after further vaccination with the same strain (34) , explaining the different findings for the effect of age between the pandemic season and season 2010-2011. It was sur prising to find that individuals with high antiCMV IgG levels showed a higher influenza titer and protection rate to seasonal vaccination. We cannot exclude that these individuals might be highantibody producers in general, as previously shown for respiratory syncytial virus and the response to other respira tory viruses (50) . Also, the total group that continued to season 2010-2011 with the study was smaller (n = 128) and had a higher number of previous vaccinations than the group of the pandemic season (n = 263), complicating the adjusted analysis. Different results were obtained for using seroconversion rate instead of protection rate as definition of responder on the seasonal vac cination. A positive effect of high antiCMV levels group was not observed on the seroconversion rate (data not shown). This shows the importance for correcting in our statistical model for these factors and strongly implies caution with interpretations of CMVinduced effects in small study groups or nonadjusted studies as reported in literature.
Important strengths of our study compared to others are the use of a novel influenza vaccine strain, the relatively large groups of study subjects in the pandemic season and the adjusted analysis with the GEE model. Since aging and latent CMV infection are thought to affect the immune system both independently and by interacting with each other, separation of these factors in analysis is crucial (51) . A limitation of the study is that the study population consists of health care workers who received repeated previous influenza vaccinations. Individuals with repeated previous seasonal influenza vaccinations show in general higher prevaccination titers than firsttime vaccinated individuals (44) . Even in the pandemic season, cross reactiv ity was reported for the H1N1pdm strain (52, 53) . Together with potential natural exposure to the H1N1pdm strain just before the study, this may explain the detectable titers before pandemic vaccination in this study. The seasonal 2009 vaccina tion 3 weeks before the study in the pandemic season indeed increased the pandemic pretiter (data not shown). However, vaccine history of the past years preceding the vaccine trial of the study subjects was reported and was adjusted for in the analysis. Importantly, pretiters did not affect the study results, since individuals in our study without detectable pretiters (n = 203) for pandemic influenza vaccination showed compa rable results for the effect of CMV infection for the pandemic season (data not shown).
The influenza response in humans is complex and raises the question if influenza vaccination is the best model to investigate the effect of latent CMV infection on vaccine responses A less complicated model, in which a vaccine for people that are truly naïve is used, might be a better study design for this question. However, we consider that influenza vaccination represents the most relevant because of its high societal importance. Therefore, knowledge on the effect of CMV infection on the influenza anti body response is of great importance.
In conclusion, we used a novel influenza vaccine strain to investigate the effect of age and latent CMV infection on the de novo immune response to influenza. We found indeed already impaired antibody responses to vaccination in adults with increasing age, but latent CMV infection did not impair the influenza virusspecific antibody response. Thereby, we show that CMV infection does not per se enhance the agerelated impaired immunity as assumed, but if anything might give opposite effects. A model in which CMV infection boosts the immune system during adulthood, while in older adults CMV infection enhances the aging of the immune system, might be appropriate. These results are important in the decision to invest in preventing latent CMV infection in healthy individuals through strategies such as CMV vaccination.
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